WHO expects anti-malarial drug hydroxychloroquine safety findings by mid-June
Image Credit: shortpedia
WHO said that it will conduct a swift review of data on hydroxychloroquine by mid-June after the global health body suspended the use of HCQ in a trial on the treatment of COVID-19 patients due to safety concerns. US President Trump had called the HCQ a 'game-changer' drug in the treatment of coronavirus but the WHO on Monday said that it will not use the drug in its multi-country trial, called Solidarity, due to safety issues.